Headquartered in Newtown Square, PA Fiscal year ends September NASDAQ: AVBP arrivent.com
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing differentiated cancer therapies. Its lead candidate, firmonertinib, is an oral, brain-penetrant, mutation-selective EGFR inhibitor approved in China for classical EGFR mutations in NSCLC and currently in global pivotal Phase 3 trials for uncommon EGFR mutations including exon 20 insertions (FURVENT trial) and PACC mutations (ALPACCA trial). Firmonertinib has received FDA Breakthrough Therapy Designation and Orphan Drug Designation. The company is also building an antibody drug conjugate (ADC) pipeline including ARR-217, a CDH17-targeted ADC for gastrointestinal cancers being developed with Lepu Biopharma, and ARR-002, a first-in-class dual-targeting MUC16/NaPi2b tetravalent ADC for ovarian and endometrial cancers. ArriVent partners with Shanghai Allist Pharmaceuticals for development and commercialization of firmonertinib and ARR-002 in Greater China while retaining global rights outside that territory. Updated
Pre-Market Stock Futures: The futures are trading flat after a solid start to the shortened Christmas holiday week. All of the major indices finished the day higher, but with the big event…
Warren Buffett has purchased more of his favorite energy stock. Other notable insider buying in the past week came from CEOs.
As January wound to a close, beneficial owners, executives, and other insiders took advantage of public offerings of stock at these biotech companies.
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing differentiated cancer therapies.
The Wall Street consensus 12-month price target for AVBP is $44.70.
